Articles
A starting dose of regorafenib (Stivarga) 80 mg daily with dose escalation to 160 mg daily was better tolerated than starting at 160 mg daily, with a trend toward improved survival in the management of patients with metastatic colorectal cancer.
Among the 84 patients, 7 had partial responses with the combination of atezolizumab (Tecentriq) and cobimetinib (Cotellic). The median duration of response was 14.3 months.
The combination cohort consisted of 119 patients who received nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by nivolumab 3 mg/kg every 2 weeks. The median follow-up was 13.4 months.
“We find that T-cells with highly activated glycolysis pathways ended up performing worse when we tried to make them into CAR T-Cells. Substituting and supplementing heavily with fatty acids did seem to improve this a little,” said David M. Barrett, MD, PhD, at the 2018 American Association for Cancer Research annual meeting.
Current National Comprehensive Cancer Network guidelines recommend initiating radiation therapy within 6 weeks of tumor resection, but the benefits of shorter time to radiation therapy, including locoregional control and survival, remain inconclusive.
“It is time for us to bury the concept of maximum-tolerated dose in the world of targeted therapy,” according to Allen S. Lichter, MD, FASCO.
While the industry does its part to improve the quality and completeness of applications, the FDA is taking action to enhance the efficiency of its review process.
Patients with indolent subtypes of NHL have a relatively good prognosis with a median survival as long as 20 years, although these subtypes of the disease are typically not curable in advanced stages.
Ovarian cancer is an avaricious tumor that can extend throughout the entire abdominal cavity. It is one of the most difficult diseases to diagnose and the most lethal gynecologic malignancy, being the fifth leading cause of cancer death in women in the United States.